argenx

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

argenx Announces Annual General Meeting of Shareholders on May 2, 2023

VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis ( gMG) who are anti-acetylcholine receptor (AChR) antibody positive

argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis

argenx SE (NASDAQ:ARGX ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Tazeen Ahmad - Bank of America Securities Rajan Sharma - Goldman Sachs Thomas Smith - SVB Securities Brendan Smith - Cowen Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Manos Mastorakis - Deutsche Bank Alex Nackenoff - Raymond James Allison Bratzel - Piper Sandler Matthew Harrison - Morgan Stanley Alex Thompson - Stifel Will Olds - Evercore Joel Beatty - Baird Douglas Tsao - H. C. Wainwright James Gordon - JPMorgan Joon Lee - Truist Securities Charles Pitman - Barclays Operator Good morning.

argenx SE (ARGX) Q4 2022 Earnings Call Transcript

$ 1 7 3 million in fourth quarter and $ 401 million in full year 2022 VYVGART® (efgartigimod alfa- fcab ) global net product sales

argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update

argenx Announces Planned Transition of Chief Operating Officer

argenx Appoints Steve Krognes to Board of Directors

February 23 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 2, 2023 at 2:30 pm CET (8:30 am ET) to discuss its full year 2022 financial results and provide a fourth quarter business update.

argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023

argenx pre-announced strong Q4 net sales of Vyvgart in early January. The PDUFA date for subcutaneous efgartigimod was pushed back by three months, which means the $98 million Priority Review voucher went to waste.

argenx: Priority Review Voucher Goes To Waste And Why SC Efgartigimod Is Important

argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod

argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

argenex SE (ARGX) Upgraded to Buy: What Does It Mean for the Stock?

Reported $ 40 2 million in preliminary * full-year 2022 global net VYVGART sales

argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline

January 3 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT.

argenx to Present at 41st Annual J.P. Morgan Healthcare Conference

AbbVie

Abbott Labs

Alnylam Pharmaceuticals

Amgen

AstraZeneca

Baxter

Bayer AG

BeiGene

Biogen

Bristol-Myers

United States Brent Oil Fund LP

BioNTech SE

CSL Ltd

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Gilead Sciences

Genmab - ADR

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Johnson & Johnson

Eli Lilly

Merck

Moderna

Novo Nordisk

Novartis

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Pfizer

Invesco Dynamic Oil & Gas Services ETF

Reckitt Benckiser Group PLC

Regeneron Pharmaceuticals

Roche Holding AG

Royalty Pharma

Seagen

Takeda Pharmaceutical

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

Vertex Pharmaceuticals

SPDR S&P Oil & Gas Exploration & Production ETF

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

argenx Appoints Ana Cespedes to Board of Directors

First immune thrombocytopenia (ITP) pl enary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease

argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia

Amsterdam, the Netherlands – November 30, 2022 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an agreement to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) for $102 million. A PRV entitles the holder to FDA priority review of a single Biologics License Application (BLA), which reduces the target review period and may lead to an expedited approval.

argenx Enters Into Agreement To Acquire Priority Review Voucher

- Prescription Drug User Fee Act (PDUFA) target action date is March 2 0 , 2023

argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

Vyvgart once again exceeded sales expectations by generating $131.3 million in net sales in the third quarter. Potential approval of subcutaneous Vyvgart in 1H 2023 and geographic expansion should fuel the continued growth of Vyvgart next year.

argenx: Vyvgart Continues To Perform Well, Key Pipeline Catalyst Next Quarter

argenx Reports Third Quarter 2022 Financial Results and Provides Business Update

argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for argenx (ARGX)

BioMarin Pharmaceutical

Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.

4 Biotech Stocks Set to Outpace Q3 Earnings Estimates

argenex SE (ARGX) Upgraded to Buy: Here's Why

October 20 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 27, 2022 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2022 financial results and provide a business update.

argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022

Scientific presentations demonstrate argenx's leadership in FcRn blockade and commitment to innovati ng for patients across multiple neuromuscular diseases

argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings

News for argenx Stock (ARGX)